
## **Learning Objectives**

By the end of this lecture, you should be able to:

1. Define **chemotherapy** and understand the principles of **antimicrobial chemotherapy**.
    
2. Describe the concept of **selective toxicity**.
    
3. List the **main classes of antibacterial agents**.
    
4. Outline the **mechanisms of action** of key antibiotic classes.
    
5. Recognise the **impact of antimicrobial resistance (AMR)** on modern medicine.
    

---

## **1. What is Chemotherapy?**

- The use of **natural or synthetic chemical substances** to inhibit or destroy **invading organisms** or **cancerous cells**.
    
- **Antibiotics** and **antibacterials** are terms often used interchangeably in this context.
    

üß† **Key Concept:**  
Antimicrobial chemotherapy targets **bacteria or pathogens** without harming host cells.

---

## **2. Historical Background of Antibiotic Discovery**

### **Paul Ehrlich (1854‚Äì1915)**

- Pioneered **selective toxicity** ‚Äì drugs can kill pathogens without harming the host.
    
- Discovered **Salvarsan**, the first treatment for _syphilis_ (kills _Trypanosomes_).
    
- Introduced the term **chemotherapy**.
    
- Found that microbes could become **resistant**, but resistance was **specific to the compound**.
    

**Exam Focus:** Ehrlich = _Selective toxicity & Salvarsan_.

---

### **Gerhard Domagk (1895‚Äì1964)**

- Discovered **Prontosil**, the first **sulfonamide antibiotic** (red dye).
    
- Shown later that its active metabolite = **sulphanilamide** (non-dye antibacterial).
    
- Developed the concept of **rational drug design** ‚Äî designing agents based on target mechanisms.
    
- Later contributed to **anti-tuberculosis drug development**.  
    üèÖ **Nobel Prize in 1939.**
    

---

### **Alexander Fleming (1928)**

- Discovered **Penicillin** by chance (_Penicillium mold_ inhibited bacterial growth).
    
- Published discovery as a **bacteriological observation**, not as therapy.
    
- Warned about potential **antimicrobial resistance (AMR)**.
    

---

### **Florey and Chain (1940s)**

- Recognised therapeutic potential of **penicillin**.
    
- Scaled up production using **fermentation** during WWII.
    
- **Extracted penicillin from patients‚Äô urine** due to scarcity!  
    üèÖ **Shared Nobel Prize (1945)** with Fleming.
    

---

### **Selman Waksman & Albert Schatz (1943)**

- Screened **soil bacteria** (Streptomyces species) for antibiotics.
    
- Discovered **Streptomycin** ‚Äî first antibiotic effective against _Mycobacterium tuberculosis_.
    
- Introduced **systematic screening** of natural products.
    

---

### **The Streptomycin Trial (1948)**

- Early **randomised controlled trial**:
    
    - 6-month mortality ‚Üì from **27% (bed rest)** ‚Üí **7% (streptomycin)**.
        
    - But 5-year resistance developed in 35/41 treated patients.  
        üß† **Lesson:** Antibiotics improve outcomes but resistance emerges rapidly.
        

---

## **3. Summary of Antibiotic Discovery Approaches**

|Mechanism|Example|Key Point|
|---|---|---|
|**Rational design**|Sulfonamides|Based on theory of chemical reactivity|
|**Chance discovery**|Penicillin|Serendipitous observation|
|**Systematic screening**|Streptomycin|Natural product search|

---

## **4. Selective Toxicity ‚Äì The Core Principle**

**Definition:**  
Drugs should be **toxic to pathogens**, but **safe for host tissues**.  
‚Üí Relies on **biochemical differences** between microbial and host cells.

---

### **Therapeutic Index (TI)**

TI=LD50ED50\text{TI} = \frac{\text{LD}_{50}}{\text{ED}_{50}}TI=ED50‚ÄãLD50‚Äã‚Äã

- **LD‚ÇÖ‚ÇÄ** = dose lethal to 50% of population
    
- **ED‚ÇÖ‚ÇÄ** = dose effective in 50% of population
    
- Higher TI = safer drug
    

| Example                                 | Toxicity Profile                                 |
| --------------------------------------- | ------------------------------------------------ |
| **Penicillins** (cell wall syntesis)    | Very safe; large doses tolerated                 |
| **Aminoglycosides** - Therapeutic index | Narrow TI; nephrotoxic & ototoxic                |
| **Isoniazid, Pyrazinamide**             | May cause **hepatotoxicity** independent of dose |
![[Pasted image 20251111143743.png]]
---

## **5. Bacterial Cell Structure ‚Äì Targets for Antibiotics**

Main target sites include:

- **Cell wall synthesis**
    
- **Cell membrane integrity**
    
- **Protein synthesis (ribosomes)**
    
- **DNA/RNA synthesis**
    
- **Metabolic pathways (e.g., folate)**
    

---

## **6. Cell Wall Inhibitors**

### **A. Peptidoglycan Structure**

- Composed of **N-acetylglucosamine (NAG)** and **N-acetylmuramic acid (NAM)**.
    
- Cross-linked by **short peptides** ‚Üí forms rigid lattice.
    
- Absent in human cells ‚Üí ideal for **selective toxicity**.  
    üß† **Gram-positive bacteria** have _thicker_ peptidoglycan layers.
    
![[Pasted image 20251111143909.png]]
---

### **B. Antibiotic Classes Targeting Cell Wall**

| Class                                                                                           | Target                             | Mechanism                            | Example                                                                                    |
| ----------------------------------------------------------------------------------------------- | ---------------------------------- | ------------------------------------ | ------------------------------------------------------------------------------------------ |
| **Œ≤-lactams**                                                                                   | Penicillin-binding proteins (PBPs) | Inhibit cross-linking                | Penicillin G, Flucloxacillin, Methicillin, Oxacillin, Nafcillin, Cloxacillin, Dicloxaillin |
| **Cephalosporins**<br>Oral - Cephalexin<br>Parenteral (not by oral) - Cefuroxime and Cefotaxime | PBPs                               | Similar to Œ≤-lactams                 | Cefalexin, Ceftriaxone                                                                     |
| **Glycopeptides**                                                                               | D-Ala‚ÄìD-Ala terminus               | Block transpeptidation               | Vancomycin, Teicoplanin                                                                    |
| **Cyclic peptides**                                                                             | Lipid carrier (C55-PP)             | Prevent peptidoglycan transport      | Bacitracin                                                                                 |
| **Phosphonic acids**                                                                            | MurA enzyme                        | Block first step of wall synthesis   | Fosfomycin                                                                                 |
| **Lipopeptides**                                                                                | Cell wall stress stimulon          | Depolarise membrane (Ca¬≤‚Å∫-dependent) | Daptomycin                                                                                 |

---

### **Mechanism of Action (Examples)**

- **Œ≤-lactams:** block **transpeptidase** enzymes ‚Üí weak wall ‚Üí osmotic lysis.
    
- **Vancomycin:** binds **D-Ala‚ÄìD-Ala**, preventing cross-linking.
    
- **Daptomycin:** disrupts membrane ‚Üí **ion leakage + depolarisation** ‚Üí death.
    

**Clinical Focus:**

- _Vancomycin-resistant enterococci (VRE)_ and _MRSA_ modify D-Ala ‚Üí D-Lac ‚Üí ‚Üì binding affinity.
    

---

## **7. Protein Synthesis Inhibitors**

| Class               | Ribosomal Target | Mechanism                                             | Example                                       |
| ------------------- | ---------------- | ----------------------------------------------------- | --------------------------------------------- |
| **Aminoglycosides** | 30S subunit      | Misreading of mRNA ‚Üí faulty proteins                  | Streptomycin, Gentamicin, Kanamycin, Neomycin |
| **Tetracyclines**   | 30S subunit      | Block tRNA attachment - weakly bound to the ribosomes | Doxycycline                                   |
| **Macrolides**      | 50S subunit      | Inhibit translocation                                 | Erythromycin, Azithromycin                    |
| **Chloramphenicol** | 50S subunit      | Inhibits peptidyl transferase                         | Chloramphenicol                               |
| **Clindamycin**     | 50S subunit      | Prevents peptide elongation                           | Clindamycin                                   |

üß† **Mechanistic difference:**

- Aminoglycosides = bactericidal
    
- Others (tetracyclines, macrolides) = bacteriostatic
    

**Clinical Tip:**  
Avoid combining **bactericidal + bacteriostatic** agents ‚Äî may antagonise each other.

---

## **8. Nucleic Acid Synthesis Inhibitors**

### **Fluoroquinolones**

- Synthetic broad-spectrum agents (e.g., **ciprofloxacin, ofloxacin**).
    
- Target **DNA gyrase (topoisomerase II)** ‚Üí prevent DNA supercoiling and replication.
    
- Highly effective vs _Gram-negative_ bacteria.
    
- **Resistance:** mutations in gyrase or efflux pumps.
    

**Adverse effects:** tendon rupture, QT prolongation.

---

## **9. Folate Pathway Inhibitors**

|Class|Target|Mechanism|Example|
|---|---|---|---|
|**Sulfonamides**|Dihydropteroate synthase|Compete with PABA|Sulfamethoxazole|
|**Trimethoprim**|Dihydrofolate reductase|Prevents tetrahydrofolate formation|Trimethoprim|

üß† **Humans obtain folate from diet ‚Üí selective toxicity achieved.**

**Combination:**  
**Co-trimoxazole = Sulfamethoxazole + Trimethoprim**  
‚Üí Synergistic inhibition of folate synthesis.

---

## **10. Miscellaneous Agents**

|Class|Mechanism|Example|
|---|---|---|
|**Polymyxins**|Disrupt outer membrane (Gram‚Äìve)|Polymyxin B, Colistin|
|**Rifamycins**|Inhibit RNA polymerase|Rifampicin (TB treatment)|
|**Metronidazole**|Generates toxic free radicals in anaerobes|Metronidazole|

---

## **11. Key Concept: Antimicrobial Resistance (AMR)**

- **Natural selection** ‚Üí survival of resistant bacteria after exposure.
    
- **Mechanisms of resistance:**
    
    1. Enzyme production (e.g. **Œ≤-lactamases**)
        
    2. Altered drug target (e.g. MRSA PBP2a)
        
    3. Reduced permeability or increased efflux
        
    4. Bypass of inhibited pathway
        

üß† **Clinical Relevance:**

- Overuse and misuse of antibiotics ‚Üí global rise in AMR.
    
- Resistant infections (MRSA, MDR-TB, CRE) = major hospital concern.
    

---

## **12. Therapeutic Summary Table**

|Target|Major Drug Classes|Example|
|---|---|---|
|**Cell wall**|Œ≤-lactams, glycopeptides, phosphonates|Penicillin, Vancomycin|
|**Cell membrane**|Lipopeptides, polymyxins|Daptomycin|
|**Protein synthesis (30S)**|Aminoglycosides, tetracyclines|Streptomycin, Doxycycline|
|**Protein synthesis (50S)**|Macrolides, chloramphenicol, clindamycin|Erythromycin|
|**DNA synthesis**|Fluoroquinolones|Ciprofloxacin|
|**Folate metabolism**|Sulfonamides, trimethoprim|Co-trimoxazole|

---

## ‚úÖ **Exam Focus Summary**

|Topic|Key Point|
|---|---|
|**Selective toxicity**|Toxic to pathogen, safe for host|
|**Therapeutic index**|LD50 / ED50; higher = safer|
|**Main bacterial targets**|Cell wall, membrane, ribosomes, DNA/RNA, folate pathway|
|**Œ≤-lactam mechanism**|Blocks transpeptidation ‚Üí weak wall|
|**Vancomycin mechanism**|Binds D-Ala‚ÄìD-Ala terminus|
|**Aminoglycosides**|30S ‚Üí misreading mRNA|
|**Macrolides**|50S ‚Üí block translocation|
|**Sulfonamides + trimethoprim**|Folate synthesis inhibitors (synergistic)|
|**Fluoroquinolones**|Inhibit DNA gyrase|
|**AMR mechanisms**|Enzyme degradation, altered target, efflux, permeability loss|

---

## üß© **Clinical Pearls**

- **Penicillin allergy** ‚Üí use macrolide or cephalosporin (if mild).
    
- **Vancomycin** reserved for MRSA or severe Gram+ infections.
    
- **Aminoglycosides** cause ototoxicity; monitor renal function.
    
- **Co-trimoxazole** used for _Pneumocystis jirovecii_ pneumonia.
    
- **Fluoroquinolones** avoid in children/pregnancy (cartilage damage).